Innate Pharma Advances Key Pipeline Assets While Implementing Strategic Restructuring
核心洞察
Innate Pharma received FDA Breakthrough Therapy Designation for lacutamab in Sézary syndrome (搜索) and is nearing completion of Phase 3 trial protocol preparation following regulatory discussions.
The company's Nectin-4 (搜索) ADC IPH4502 is progressing through Phase 1 enrollment with first patient data expected in H1 2026, while AstraZeneca's PACIFIC-9 trial with monalizumab completed enrollment.
Innate plans to reduce staffing by approximately 30% and focus resources on three highest-value assets: IPH4502, lacutamab, and monalizumab, with cash runway extending to Q3 2026.
Innate Pharma reported significant clinical progress across its key pipeline assets while announcing a strategic restructuring to focus resources on its highest-value programs. The French biotechnology company received FDA Breakthrough Therapy Designation for lacutamab and advanced its Nectin-4 (搜索) ADC through Phase 1 enrollment, positioning itself for multiple data readouts over the next 18 months.
FDA Breakthrough Designation Accelerates Lacutamab Development
In February 2025, the FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary syndrome (搜索) based on Phase 2 TELLOMAK trial results. The designation, intended to accelerate development and regulatory review for drugs treating serious conditions, was supported by long-term follow-up data presented at the 2025 ASCO Annual Meeting.
The updated TELLOMAK data reinforced lacutamab's clinical activity in heavily pretreated patients post-mogamulizumab. In Sézary syndrome (搜索), lacutamab achieved a 42.9% overall response rate with a median duration of response of 25.6 months. In mycosis fungoides (搜索), responses were observed regardless of KIR3DL2 (搜索) expression, with a median progression-free survival of 10.2 months. The treatment was well tolerated across both cohorts with sustained improvements in quality of life.
"Preparation of the confirmatory Phase 3 trial protocol is close to completion, following discussions with the FDA and EMA," the company stated. Innate is evaluating potential paths forward to advance lacutamab toward Phase 3 initiation, including discussions with partners and investors.
IPH4502 Nectin-4 ADC Shows Promising Preclinical Profile
Innate's novel topoisomerase I inhibitor ADC targeting Nectin-4 (搜索) continued enrollment in its Phase 1 study, which began dosing patients in January 2025. The study will assess safety, tolerability, and preliminary efficacy in advanced solid tumors expressing Nectin-4, including urothelial carcinoma (搜索), non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers. Enrollment of approximately 105 patients is expected to complete by end of 2025 or first quarter 2026.
New preclinical data presented at the American Association for Cancer Research Annual Meeting 2025 demonstrated IPH4502's superior anti-tumor activity compared to enfortumab vedotin in urothelial carcinoma (搜索) models with low or heterogeneous Nectin-4 (搜索) expression, as well as in enfortumab vedotin-resistant models. Beyond urothelial cancer, IPH4502 exhibited anti-tumor activity in preclinical models of triple-negative breast cancer (搜索), head and neck squamous cell carcinoma, and esophageal cancer.
AstraZeneca Partnership Advances Monalizumab in Lung Cancer
The Phase 3 PACIFIC-9 trial evaluating durvalumab in combination with monalizumab or oleclumab in patients with unresectable Stage III non-small cell lung cancer (搜索) completed enrollment. The trial, conducted by partner AstraZeneca, is expected to deliver high-level readout in H2 2026.
Supporting data from the Phase 2 NeoCOAST-2 trial presented at ASCO 2025 showed the durvalumab, monalizumab, and chemotherapy combination achieved 25.7% pathological complete response and 50.0% major pathologic response in resectable NSCLC patients.
Strategic Restructuring and Financial Position
Innate announced plans to prioritize investment in its three highest-value clinical assets: IPH4502, lacutamab, and monalizumab. The company intends to streamline its organization with staffing levels expected to decrease by approximately 30% through a redundancy plan subject to consultation with the Workers' Council and French regulatory approval. Implementation is expected to complete during the first half of 2026.
Chief Scientific Officer Eric Vivier will return to academic research full-time effective January 1, 2026, continuing to support the company's innovation as an advisor to the R&D Committee. Chief Operating Officer Yannis Morel will assume CSO responsibilities while continuing oversight of preclinical research and development.
The company reported cash, cash equivalents, short-term investments and financial assets of €70.4 million as of June 30, 2025, providing anticipated cash runway until end Q3 2026. Sanofi invested €15 million in new equity in April 2025, subscribing to 8,345,387 new ordinary shares at €1.7974 per share, representing 9.05% of outstanding shares.
Financial Performance Reflects Pipeline Transition
Revenue and other income decreased to €4.9 million in the first half of 2025 from €12.3 million in the prior year period, primarily due to milestone payment timing differences. The company recognized no revenue from its 2016 Sanofi collaboration agreement in H1 2025 compared to €4.0 million in H1 2024, when a milestone was triggered by first patient dosing in the Phase 2 expansion of the IPH6101 trial.
Research and development expenses decreased by €8.6 million to €20.5 million, representing 67.8% of total operating expenses. The decrease reflected the phasing of studies, including maturity of lacutamab clinical studies, discontinuation of certain preclinical programs, and initiation of the IPH4502 Phase 1 trial.
The company reported a net loss of €21.3 million for the first half of 2025 compared to net income of €24.8 million in the prior year period, which included significant milestone payments and upfront fees from partnership agreements.